JP2021502329A - Ｒｈｏａドミナントネガティブフォームを使用して癌を治療するための組成物および方法 - Google Patents

Ｒｈｏａドミナントネガティブフォームを使用して癌を治療するための組成物および方法 Download PDF

Info

Publication number
JP2021502329A
JP2021502329A JP2020520153A JP2020520153A JP2021502329A JP 2021502329 A JP2021502329 A JP 2021502329A JP 2020520153 A JP2020520153 A JP 2020520153A JP 2020520153 A JP2020520153 A JP 2020520153A JP 2021502329 A JP2021502329 A JP 2021502329A
Authority
JP
Japan
Prior art keywords
cancer
rhoa
dominant negative
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020520153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502329A5 (https=
Inventor
アダム バス，
アダム バス，
ハイシェン ジャン，
ハイシェン ジャン，
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド, デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2021502329A publication Critical patent/JP2021502329A/ja
Publication of JP2021502329A5 publication Critical patent/JP2021502329A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020520153A 2017-11-08 2018-11-05 Ｒｈｏａドミナントネガティブフォームを使用して癌を治療するための組成物および方法 Pending JP2021502329A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762583166P 2017-11-08 2017-11-08
US62/583,166 2017-11-08
PCT/US2018/059188 WO2019094326A1 (en) 2017-11-08 2018-11-05 Compositions and methods for treating cancer using rhoa dominant negative forms

Publications (2)

Publication Number Publication Date
JP2021502329A true JP2021502329A (ja) 2021-01-28
JP2021502329A5 JP2021502329A5 (https=) 2021-12-16

Family

ID=66439269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520153A Pending JP2021502329A (ja) 2017-11-08 2018-11-05 Ｒｈｏａドミナントネガティブフォームを使用して癌を治療するための組成物および方法

Country Status (7)

Country Link
US (1) US11957739B2 (https=)
EP (1) EP3706751A4 (https=)
JP (1) JP2021502329A (https=)
CN (1) CN111278443A (https=)
AU (1) AU2018365800A1 (https=)
CA (1) CA3076269A1 (https=)
WO (1) WO2019094326A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957739B2 (en) 2017-11-08 2024-04-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer using RHOA dominant negative forms
SE2000055A1 (sv) * 2020-03-15 2021-09-16 Martin Ivanov Denev Användande av fotohydrauliskt mekanisk chock, för selektiv sprängning av relativ svagare cellmembranen av cancerceller, vilka har svagare cellmembran än friska celler
CN113278706B (zh) * 2021-07-23 2021-11-12 广州燃石医学检验所有限公司 一种用于区分体细胞突变和种系突变的方法
WO2024059823A1 (en) * 2022-09-15 2024-03-21 Iview Therapeutics, Inc. Self-complementary AAV vectors carrying dominant negative RhoA and methods of use to treat ocular diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1274463A2 (en) * 1999-12-10 2003-01-15 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
WO2003030836A2 (en) * 2001-10-12 2003-04-17 Case Western Reserve University Neuronal regeneration
WO2005072141A2 (en) * 2004-01-16 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of rhoa signaling
US7951924B2 (en) 2004-11-12 2011-05-31 University Of South Florida RhoB variants and methods of use
US7507534B2 (en) 2005-09-01 2009-03-24 National Health Research Institutes Rapid efficacy assessment method for lung cancer therapy
US20070161060A1 (en) 2005-09-07 2007-07-12 Anderson Richard A Screening method for identifying an agent that modulates PIPKIgamma trafficking of E-cadherin
ES2623447T3 (es) 2007-12-19 2017-07-11 Rhovac Aps Inmunoterapia basada en RhoC
WO2009089040A1 (en) * 2008-01-11 2009-07-16 Jaffrey Samie R Methods for expressing proteins in axons
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
BR112013026199A2 (pt) * 2011-04-15 2017-11-07 Compugen Ltd polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US11957739B2 (en) 2017-11-08 2024-04-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer using RHOA dominant negative forms

Also Published As

Publication number Publication date
US11957739B2 (en) 2024-04-16
AU2018365800A1 (en) 2020-04-02
EP3706751A1 (en) 2020-09-16
CN111278443A (zh) 2020-06-12
US20200261550A1 (en) 2020-08-20
CA3076269A1 (en) 2019-05-16
EP3706751A4 (en) 2021-08-18
WO2019094326A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
US20210189342A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
CN109689062B (zh) 使用抗PI3Kβ和抗免疫检查点药剂的组合治疗PTEN缺陷型上皮癌的方法
US11740242B2 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
CA2944903A1 (en) Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
WO2018148378A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
CA2968352A1 (en) Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
AU775583B2 (en) Methods for the diagnosis and treatment of metastatic prostate tumors
US20200149042A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
JP2021502329A (ja) Ｒｈｏａドミナントネガティブフォームを使用して癌を治療するための組成物および方法
AU2019227641B2 (en) Methods for treating cancer using combinations of anti-BTNL2 and immune checkpoint blockade agents
US20250146076A1 (en) Alk gene fusions and uses thereof
US12050219B2 (en) Modulating biomarkers such as SPP to increase tumor immunity and improve the efficacy of cancer immunotherapy
US20220289854A1 (en) Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
US20240263240A1 (en) Cd274 mutations for cancer treatment
EP4399330A1 (en) Gene fusions in sarcoma
CA2621992C (en) Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
JP4025645B2 (ja) Ｐｉｂｆ濃度測定によるガン患者の検査方法
EP1553414A1 (en) Methods for the diagnosis and treatment of metastatic prostate tumors
JPWO2005061704A1 (ja) 癌の予防・治療剤
US20190240327A9 (en) Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
AU2026202687A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
HK40006303B (en) Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
HK40006303A (en) Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
HK40028190A (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230517